In a report released today, Peter Lawson from Barclays maintained a Hold rating on Blueprint Medicines (BPMC – Research Report), with a price ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chemomab Therapeutics (CMMB – Research Report) ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $50 million in its fourth quarter. On a per-share basis, the Cambridge, ...

BPMC stock opened at $93.94 on Thursday. Blueprint Medicines has a 1-year low of $77.57 and a 1-year high of $121.90. The business has a 50-day moving average price of $99.61 and a 200 day moving ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago.

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Thursday reported a loss of $50 million in its fourth quarter. On a per-share basis, the Cambridge ...